363 related articles for article (PubMed ID: 31601640)
1. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA
Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640
[TBL] [Abstract][Full Text] [Related]
2. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
Horii T; Oikawa Y; Atsuda K; Shimada A
J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
[TBL] [Abstract][Full Text] [Related]
3. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Colacci M; Fralick J; Odutayo A; Fralick M
Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
[TBL] [Abstract][Full Text] [Related]
5. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
[TBL] [Abstract][Full Text] [Related]
6. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Danne T; Biester T; Kordonouri O
Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
[TBL] [Abstract][Full Text] [Related]
7. Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Peters AL; McGuire DK; Danne T; Kushner JA; Rodbard HW; Dhatariya K; Sawhney S; Banks P; Jiang W; Davies MJ; Lapuerta P
Diabetes Care; 2020 Nov; 43(11):2713-2720. PubMed ID: 32928957
[TBL] [Abstract][Full Text] [Related]
8. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence.
Khunti K; Aroda VR; Bhatt DL; Bozkurt B; Buse JB; Heerspink HL; Inzucchi SE; Lam CSP; Marx N; McMurray JJV; Solomon SD; Kosiborod MN
Diabetes Obes Metab; 2022 Nov; 24(11):2071-2080. PubMed ID: 35801339
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
[TBL] [Abstract][Full Text] [Related]
11. Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes.
Rendell MS
Expert Rev Endocrinol Metab; 2018 Nov; 13(6):333-339. PubMed ID: 30379091
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors.
Jeon JY; Kim SK; Kim KS; Song SO; Yun JS; Kim BY; Kim CH; Park SO; Hong S; Seo DH; Seo JA; Noh JH; Kim DJ;
Diabetes Metab; 2019 Oct; 45(5):453-457. PubMed ID: 30639566
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
Goldenberg RM; Gilbert JD; Hramiak IM; Woo VC; Zinman B
Diabetes Obes Metab; 2019 Oct; 21(10):2192-2202. PubMed ID: 31183975
[TBL] [Abstract][Full Text] [Related]
16. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
17. Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.
Stougaard EB; Kristensen PL; Kielgast U; Andersen HU; Hamid Y; Gæde PH; Søndergaard E; Dørflinger GH; Fjeldborg KK; Hansen KW; Thomsen HH; Al-Imar TMJ; Røder M; Sridhar VS; Cherney D; Rossing P; Persson F
Diab Vasc Dis Res; 2022; 19(5):14791641221130043. PubMed ID: 36262089
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sotagliflozin in treating diabetes type 1.
Rendell MS
Expert Opin Pharmacother; 2018 Feb; 19(3):307-315. PubMed ID: 29212386
[TBL] [Abstract][Full Text] [Related]
19. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
Sims H; Smith KH; Bramlage P; Minguet J
Diabet Med; 2018 Aug; 35(8):1037-1048. PubMed ID: 29637608
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and Clinical Characteristics of Adults Presenting With Sodium-Glucose Cotransporter-2 Inhibitor-Associated Diabetic Ketoacidosis at a Canadian Academic Tertiary Care Hospital.
Clark A; Mohammed AS; Raut A; Moore S; Houlden R; Awad S
Can J Diabetes; 2021 Apr; 45(3):214-219. PubMed ID: 33046401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
